Ernest C. Borden

21.9k total citations · 4 hit papers
311 papers, 16.2k citations indexed

About

Ernest C. Borden is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ernest C. Borden has authored 311 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Oncology, 120 papers in Immunology and 99 papers in Molecular Biology. Recurrent topics in Ernest C. Borden's work include Cytokine Signaling Pathways and Interactions (67 papers), interferon and immune responses (51 papers) and Immunotherapy and Immune Responses (31 papers). Ernest C. Borden is often cited by papers focused on Cytokine Signaling Pathways and Interactions (67 papers), interferon and immune responses (51 papers) and Immunotherapy and Immune Responses (31 papers). Ernest C. Borden collaborates with scholars based in United States, India and Canada. Ernest C. Borden's co-authors include Daniel J. Lindner, Younan A. Sidky, Barbara Jacobs, George R. Stark, Douglas W. Leaman, Mamta Chawla‐Sarkar, Joseph M. Carlin, E. Knight, Cathryn Rankin and Ganes C. Sen and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Ernest C. Borden

306 papers receiving 15.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interferons at age 50: past, current and future impact on biomedicine

2007 904 citations Ernest C. Borden et al. profile →
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

2008 768 citations Ernest C. Borden et al. profile →
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

2006 594 citations Ernest C. Borden et al. profile →
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

2008 436 citations Ernest C. Borden et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ernest C. Borden United States	66	6.0k	5.8k	4.9k	3.0k	1.7k	311	16.2k
Simone Mocellin Italy	59	3.1k 0.5×	5.2k 0.9×	3.2k 0.7×	2.3k 0.8×	1.3k 0.8×	279	11.8k
Christoph Becker Germany	67	9.3k 1.5×	4.6k 0.8×	6.8k 1.4×	1.9k 0.6×	2.3k 1.3×	187	20.1k
Thomas Krausz United States	60	1.9k 0.3×	3.4k 0.6×	3.5k 0.7×	4.2k 1.4×	1.3k 0.7×	222	13.4k
Tohru Tsujimura Japan	55	9.5k 1.6×	2.8k 0.5×	7.1k 1.4×	1.9k 0.7×	2.3k 1.3×	213	18.4k
Tae Il Kim South Korea	54	2.5k 0.4×	3.4k 0.6×	3.2k 0.6×	2.3k 0.8×	823 0.5×	519	11.9k
Takehiko Sasazuki Japan	71	8.2k 1.4×	2.9k 0.5×	5.8k 1.2×	1.2k 0.4×	1.7k 1.0×	351	18.7k
Takanori Kanai∥ Japan	62	4.4k 0.7×	4.4k 0.8×	5.7k 1.2×	1.9k 0.7×	1.4k 0.8×	551	17.9k
Agnès Viale United States	64	2.0k 0.3×	5.4k 0.9×	12.1k 2.5×	2.9k 1.0×	3.9k 2.3×	139	20.7k
Atul K. Bhan United States	76	9.1k 1.5×	3.0k 0.5×	3.2k 0.7×	1.4k 0.5×	710 0.4×	235	19.5k
Kohzoh Imai Japan	75	2.6k 0.4×	5.4k 0.9×	10.5k 2.1×	1.9k 0.6×	3.4k 1.9×	434	18.8k

Countries citing papers authored by Ernest C. Borden

Since Specialization

Citations

This map shows the geographic impact of Ernest C. Borden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernest C. Borden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernest C. Borden more than expected).

Fields of papers citing papers by Ernest C. Borden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernest C. Borden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernest C. Borden. The network helps show where Ernest C. Borden may publish in the future.

Co-authorship network of co-authors of Ernest C. Borden

This figure shows the co-authorship network connecting the top 25 collaborators of Ernest C. Borden. A scholar is included among the top collaborators of Ernest C. Borden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernest C. Borden. Ernest C. Borden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Łuszczek, Wioleta, Venugopalan Cheriyath, Tarek Mekhail, & Ernest C. Borden. (2010). Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression. Molecular Cancer Therapeutics. 9(8). 2309–2321. 73 indexed citations

Dhawan, Deepika, et al.. (2002). Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.. PubMed. 1(14). 1255–64. 103 indexed citations

Walter, Mark R., Ronald Bordens, Tattanahalli L. Nagabhushan, et al.. (1998). Review of Recent Developments in the Molecular Characterization of Recombinant Alfa Interferons on the 40th Anniversary of the Discovery of Interferon. Cancer Biotherapy and Radiopharmaceuticals. 13(3). 143–154. 29 indexed citations

Nolten, Wolfram E., Daniel A. Goldstein, Mary J. Lindstrom, et al.. (1993). Effects of Cytokines on the Pituitary–Adrenal Axis in Cancer Patients. Journal of Interferon Research. 13(5). 349–357. 42 indexed citations

Borden, Ernest C., Kwang Taek Kim, Louise Ryan, et al.. (1992). Phase II Trials of Interferons-α and -β in Advanced Sarcomas. Journal of Interferon Research. 12(6). 455–458. 6 indexed citations

Borden, Ernest C. & Paul M. Sondel. (1990). Lymphokines and cytokines as cancer treatment.Immunotherapy realized. Cancer. 65(S3). 800–814. 78 indexed citations

Goldstein, Daniel A., Brigitte Cheuvart, D L Trump, et al.. (1990). Phase II Trial of Carboplatin in Soft-Tissue Sarcoma. American Journal of Clinical Oncology. 13(5). 420–423. 21 indexed citations

Carlin, Joseph M., Ernest C. Borden, & Gerald I. Byrne. (1989). Interferon-Induced Indoleamine 2,3-Dioxygenase Activity Inhibits Chlamydia psittaci Replication in Human Macrophages. Journal of Interferon Research. 9(3). 329–337. 115 indexed citations

Wussow, Peter von & Ernest C. Borden. (1989). Introduction. Journal of Interferon Research. 9(s1). v–v. 11 indexed citations

10.

Carlin, Joseph M., Ernest C. Borden, & Gerald I. Byrne. (1989). Enhancement of Indoleamine 2,3-Dioxygenase Activity in Cancer Patients Receiving Interferon-β _Ser. Journal of Interferon Research. 9(2). 167–173. 14 indexed citations

11.

Cheng, Yih‐Shyun E., et al.. (1988). Accumulation of Guanylate Binding Proteins in Patients Treated with Interfeons. Journal of Interferon Research. 8(3). 385–391. 10 indexed citations

12.

Schiller, Joan H., et al.. (1988). Phase II Trial of a Combination of Interferon-β _ser and Interferon-γ in Patients with Advanced Malignant Melanoma. Journal of Interferon Research. 8(5). 581–589. 21 indexed citations

13.

Trump, D L, Paul Elson, Ernest C. Borden, et al.. (1987). High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.. PubMed. 71(2). 165–9. 21 indexed citations

14.

Borden, Ernest C., et al.. (1987). Interferons: From Virus Inhibitor to Modulator of Amino Acid and Lipid Metabolism. Journal of Interferon Research. 7(5). 591–596. 10 indexed citations

15.

Byrne, Gerald I., et al.. (1986). Induction of Tryptophan Degradation In Vitro and In Vivo : A γ-Interferon-Stimulated Activity. Journal of Interferon Research. 6(4). 389–396. 160 indexed citations

16.

Merritt, James A., et al.. (1986). Modulation of 2′,5′-Oligoadenylate Synthetase in Patients Treated with Alpha-Interferon: Effects of Dose, Schedule, and Route of Administration. Journal of Interferon Research. 6(3). 189–198. 34 indexed citations

17.

Edwards, Bruce S., Robert C. Fuhlbrigge, & Ernest C. Borden. (1986). Separation of Human Natural Killer Cell Subpopulations Differentially Responsive to Interferon Potentiation. Journal of Interferon Research. 6(4). 361–372. 2 indexed citations

18.

Merritt, James A., Ernest C. Borden, & L. Andrew Ball. (1985). Measurement of 2′,5′-Oligoadenylate Synthetase in Patients Receiving Interferon-Alpha. Journal of Interferon Research. 5(1). 191–198. 47 indexed citations

19.

Gould, Michael N., et al.. (1984). Radiosensitization of Human Bronchogenic Carcinoma Cells by Interferon Beta. Journal of Interferon Research. 4(1). 123–128. 36 indexed citations

20.

Fuhlbrigge, Robert C., Bruce S. Edwards, & Ernest C. Borden. (1984). Effects of Interferon Alpha on the Sheep Erythrocyte "Receptor" of Human Lymphocytes. Journal of Interferon Research. 4(4). 499–505. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact